- Home
- NBTB vs CNTA Comparison
NBTB vs CNTA Comparison
Compare NBTB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBTB | CNTA |
|---|---|---|
| Founded | 1856 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBTB | CNTA |
|---|---|---|
| Price | $43.95 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $51.00 | $37.70 |
| AVG Volume (30 Days) | 209.9K | ★ 1.8M |
| Earning Date | 01-26-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 5.89 | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $629,728,000.00 | $15,000,000.00 |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $9.17 | N/A |
| P/E Ratio | $14.58 | ★ N/A |
| Revenue Growth | 16.88 | ★ 118.88 |
| 52 Week Low | $37.31 | $9.60 |
| 52 Week High | $52.44 | $30.58 |
Technical Indicators
Market Signals| Indicator | NBTB | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 69.05 | 45.51 |
| Support Level | $41.38 | $28.43 |
| Resistance Level | $44.48 | $30.02 |
| Average True Range (ATR) | 1.00 | 1.34 |
| MACD | 0.29 | -0.40 |
| Stochastic Oscillator | 88.66 | 18.64 |
Price Performance
Historical ComparisonAbout NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.